I. Gudz

Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.

G. Raskob, H. Büller, M. Mercuri, 2016, The Lancet. Haematology.

Rivaroxaban in Peripheral Artery Disease after Revascularization.

Manesh R. Patel, Marc P. Bonaca, Sonia S Anand, 2020, The New England journal of medicine.

Total Ischemic Event Reduction with Rivaroxaban after Peripheral Arterial Revascularization in the VOYAGER PAD Trial.

Sonia S Anand, M. Brodmann, W. Hiatt, 2021, Journal of the American College of Cardiology.

Rivaroxaban in Patients with Symptomatic Peripheral Artery Disease after Lower Extremity Bypass Surgery with Venous and Prosthetic Conduits.

H. Sillesen, L. Norgren, Sonia S Anand, 2022, Journal of vascular surgery.

Hybrid Revascularization for Aorto-Iliac Occlusive Disease with Common Femoral Artery Involvement: Early Outcomes of a Single Centre.

I. Gudz, N. Skrypnyk, V. Orynchak, 2021, Annals of vascular surgery.

Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies

P. Altmeyer, G. Rahav, D. Zeltser, 2018, Antimicrobial Agents and Chemotherapy.

Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.

G. Raskob, H. Büller, M. Mercuri, 2016, The Lancet. Haematology.